RBM17

Across TCGA pan-cancer cohorts, RBM17 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RBM17 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RBM17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RBM17 expression acts as an unfavorable survival marker.

CESC, STAD, and LIHC are the cancer types where RBM17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.167	0.798	<.001	30	view →
STAD	OS	Median	II,III,IV	0.183	0.677	.004	24	view →
LIHC	OS	Median	All	0.242	0.692	.003	21	view →
LUAD	DFS	Median	All	0.213	0.676	.012	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RBM17–CESC (OS)

Open the CESC breakdown →